ALKBH5 and neoplasm: In cohort #3, which contains randomly recruited LUAD patients with accurate tumor progression information, we found that except YTHDF1, ENO1, METTL3 and global m6A levels were positively while ALKBH5 was negatively associated with tumor stages (Fig. 7F-J), further demonstrating the important roles of m6A and ENO1 in tumor progression.